Dental Appliance to Treat SDB in Children

NCT ID: NCT05661747

Last Updated: 2022-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-03

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical hypothesis of this study is that a currently marketed mouthguard may also be able to reduce the symptoms of sleep-disordered breathing in children.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate the safety and efficacy of an mouthguard (Vivos Grow/Vivos Way) to reduce sleep-disordered breathing (SDB) in children, including:

snoring, mild to moderate obstructive sleep apnea (OSA), and upper airway resistance syndrome (UARS) in children.

The subjects enrolled in this study will be using the Vivos Grow/Vivos Way to correct orthodontic issues and must also present with signs of SDB.

The study will recruit pediatric subjects who have already elected to utilize the study device for their orthodontic treatment; if they meet the inclusion and exclusion criteria they can be included in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Snoring Apnea, Obstructive Upper Airway Resistance Syndrome Sleep-Disordered Breathing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The patient will serve as their own control.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

No masking is possible, as each child will serve as their own control in using the mouthguard, and their progress will be compared to their measurements prior to beginning the trial.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm will use Vivos Grow/Vivos Way Device

This intervention will compare measurements prior to treatment with measurements post-treatment.

Group Type EXPERIMENTAL

Vivos Grow/Vivos Way Device

Intervention Type DEVICE

Children already using the device will be monitored to determined whether it improves symptoms of SDB

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vivos Grow/Vivos Way Device

Children already using the device will be monitored to determined whether it improves symptoms of SDB

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over the age of 6 and under the age of 18 years
* Permanent dentition or mixed dentition at time of evaluation
* Diagnosis of sleep-disordered breathing (including snoring, upper airway resistance syndrome, and/or mild to moderate obstructive sleep apnea)
* Have chosen to have orthodontic treatment
* Living in the United States
* Signed Informed Consent Form

Exclusion Criteria

* Poor oral hygiene
* Uncontrolled diabetes
* Severe obstructive sleep apnea (AHI\> 10/hr)
* Enlarged tonsils of a Grade 4 (\>75% of space between pillars)
* Diagnosed with a Temporomandibular join condition (TMJ)
* Any severe breathing or respiratory disorder, such as chronic asthma, emphysema, COPD, or a similar condition
* Orthodontic braces in situ
Minimum Eligible Age

7 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vivos BioTechnologies, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Musso, DDS

Role: PRINCIPAL_INVESTIGATOR

Musso Family Dentistry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Breathing and Sleep Center

Colorado Springs, Colorado, United States

Site Status RECRUITING

Emerald Coast Dental Spa and Sleep Medicine

Panama City Beach, Florida, United States

Site Status RECRUITING

Musso Family Dentistry

Garland, Texas, United States

Site Status NOT_YET_RECRUITING

New Teeth Dental Solutions

League City, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Colette Cozean, Ph.D.

Role: CONTACT

Phone: 19498552885

Email: [email protected]

Mark Musso, DDS

Role: CONTACT

Phone: 972-840-8477

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kevin Goles, DDS

Role: primary

Tara Griffen, DDS

Role: primary

Mark Musso, DDS

Role: primary

Kalli Hale, DDS

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Kushida CA, Stevens J, Bennett M, Heit T, Klemp D, Raio D, Cozean J, Cozean C. Multicenter clinical trial for the treatment of obstructive sleep apnea with a non-permanent orthodontic intraoral device in children. Eur J Pediatr. 2025 Jun 17;184(7):424. doi: 10.1007/s00431-025-06254-x.

Reference Type DERIVED
PMID: 40526156 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VG-01

Identifier Type: -

Identifier Source: org_study_id